Recently, Hainan Xiansheng Pharmaceutical Co., Ltd., a subsidiary of Xiansheng Pharmaceutical Group, successively received two copies of the “National Drug Administration Approval Application for Pharmaceutical Supplements”, “Relin®-Amoxicillin Granules” and “An Liqing” ®-Miloxicam tablets were evaluated on the consistency of generic drugs on September 10 and September 6, respectively. Among them, Relin® was the first amoxicillin granule to pass the consistency evaluation, and Anriqing® was the first meloxicam tablet to pass the consistency evaluation.
In China, children have respiratory tract infections due to colds, fever, coughs, etc. Many parents will immediately think of Relin®, the first oral antibiotic for children in Amoxicillin in China, which has created a skin-free era for such drugs. .
With unique strawberry flavor and strict quality control, Relin® granules have a 63% market share in the Chinese amoxicillin granule retail market, becoming the first brand of oral antibiotic amoxicillin granules for children (Source: CMH) . In 2004, he entered the national medical insurance catalogue.
Anritsu® is suitable for the treatment of short-term symptoms of aggravation of osteoarthritis, long-term symptomatic treatment of rheumatoid arthritis and ankylosing spondylitis. Related studies suggest that Anritsu® has lower gastrointestinal reactions and fewer cardiovascular adverse events than other commonly used NSAIDs. At the same time, it is convenient to take, with a half-life of up to 20 hours and only one dose a day.
Consensus on Consensus Evaluation: On March 5, 2016, the General Office of the State Council officially issued the “Opinions on Conducting the Evaluation of the Consistency of Quality and Efficacy of Generic Drugs” (Guo Ban Fa [2016] No. 8), whose core goal is to comprehensively improve The quality of generic drugs, the realization of domestic generic drugs for the clinical replacement of the original drug. It is of great significance to improve the overall level of China's pharmaceutical industry, ensure the safety and effectiveness of drugs, promote the upgrading and structural adjustment of the pharmaceutical industry, and enhance international competitiveness.
